DI
DZS INC. (DZSI)·Q2 2023 Earnings Summary
Executive Summary
- DZS did not report Q2 2023 financial results; the company filed an NT 10‑Q and disclosed it would be late due to an audit committee review and a restatement of Q1 2023 related to revenue recognition timing .
- Nasdaq sent a delinquency notice for the late Form 10‑Q; DZS must submit a compliance plan and may receive an extension to February 5, 2024 if accepted .
- Liquidity was bolstered post‑quarter: DZS secured $29.7M in loans, including a $24.5M three‑year term loan at 8% with shareholder Dasan Networks, to pay down its term debt and revolver; management expects quarterly OpEx to be ~$10M lower by Q1 2024 vs Q1 2023 ($24M vs $34M) .
- Strategic upside: DZS highlighted “Build America, Buy America”/BEAD eligibility, asserting its OLTs/ONTs meet proposed waiver requirements, a potential catalyst for growth in U.S. broadband deployments .
What Went Well and What Went Wrong
What Went Well
- Financing and covenant relief: “The new financing from DNI will ease our financial covenants, lower our interest cost basis and…fully pay off our existing loans” (Charlie Vogt, CEO) .
- Cost discipline: “We expect to lower our quarterly operating spend by nearly $10 million by the first quarter of 2024 compared with the first quarter of 2023, specifically, $24 million in Q1 2024 versus $34 million in Q1 2023” .
- BEAD/BABA positioning: Management stated DZS is “among a short list of technology suppliers meeting the requirements for Optical Line Terminals (OLTs)…and Optical Network Terminals (ONTs)” under the proposed BEAD waiver, enabling compliant procurement now .
What Went Wrong
- Reporting delay and restatement: The audit committee initiated a review and Q1 2023 will be restated due to revenue recognition timing errors; Q2 2023 Form 10‑Q was delayed with no expected filing date .
- Listing compliance risk: Nasdaq notified DZS of non‑compliance for not timely filing Q2 10‑Q; DZS must submit a plan to regain compliance, creating uncertainty and headline risk .
- Credit agreement defaults: Lenders documented “Specified Defaults,” including failure to maintain minimum liquidity and minimum EBITDA, late delivery of Q2 financials, and banking relationship requirements; a limited consent permitted new loans only if proceeds repaid existing obligations promptly .
Financial Results
Note: DZS did not file Q2 2023 results due to a delayed Form 10‑Q; Q4 2022 and Q1 2023 are shown for trend. Q2 2023 cells marked N/A reference the delayed filing.
Segment breakdown – Product Technology:
Geographic mix:
KPIs (as disclosed):
Guidance Changes
Note: No formal guidance update was issued in August; Q2 10‑Q remained delayed .
Earnings Call Themes & Trends
Management Commentary
- “The new financing from DNI will ease our financial covenants, lower our interest cost basis and…fully pay off our existing loans” (Charlie Vogt, CEO) .
- “We expect to lower our quarterly operating spend by nearly $10 million by the first quarter of 2024 compared with the first quarter of 2023, specifically, $24 million in Q1 2024 versus $34 million in Q1 2023” .
- “We anticipate that 1Q 2023 will mark the low point for gross margin…we expect to deliver gross margin and earnings improvement throughout the balance of 2023” (CEO prepared remarks) .
- “Our updated full year outlook includes revenue of approximately $400 million; gross margin between 35% and 37%…Adjusted EBITDA between $22 million and $27 million” (CFO) .
- BEAD/BABA: “Assuming the…waiver…stands as proposed, DZS is among a short list of technology suppliers meeting the requirements for OLTs… and ONTs” .
Q&A Highlights
- Guidance recalibration: ~10% revenue reduction vs prior expectations driven by product launch timing (Sabre 4400 and Velocity V6) and trial conversion timing .
- Lead times: Normalizing from >52 weeks to 3–6 months, targeting 3–4 months by 2024; variability by product BOM .
- Gross margin target: Path to sustainable ~40% GM hinges on N.A./EMEA mix, third‑party manufacturing scale (Fabrinet phase II), and software pricing/cross‑sell (Xtreme, CloudCheck) .
- OpEx discipline: Sales/marketing to remain elevated; operations efficiencies and product completion to drive savings and EBITDA progression in 2024–2025 .
- Working capital: DSOs at 140 days in Q1 due to Vietnam milestone timing, ASSIA billing integration, and ERP timing; expected to fall below 100 days by year‑end .
Estimates Context
- Wall Street consensus estimates via S&P Global for DZSI Q2 2023 were unavailable in our system at the time of request; as a result, no comparison vs consensus is presented.
- Given the delayed 10‑Q and restatement review, sell‑side models are likely to revisit revenue timing, margin trajectory, liquidity and credit terms once filings resume .
Key Takeaways for Investors
- The absence of filed Q2 2023 results and the Nasdaq delinquency notice introduce near‑term headline and listing risk; monitor timing and outcomes of the audit committee review and compliance plan .
- Post‑quarter financing (~$29.7M total; $24.5M term loan at 8%) reduces near‑term covenant pressure and retires higher‑cost debt; an ABL facility is being pursued to support growth .
- Cost actions are material: management targets ~$10M quarterly OpEx reduction by Q1 2024 vs Q1 2023, supporting margin and cash flow improvements even amid revenue timing variability .
- Policy tailwinds: Claimed BEAD/BABA eligibility for OLTs/ONTs positions DZS to benefit from U.S. broadband subsidies; track any awards and U.S. order flow .
- Medium‑term thesis rests on higher‑margin product ramp (Sabre 4400, Velocity V6) and software attach (Xtreme), driving GM toward ~40% and EBITDA scaling; execution on trials/design wins remains the key gating factor .
- Near‑term trading: Expect volatility around filing status updates/restatement scope; upside catalysts include filing resumption, confirmation of BEAD/BABA orders, and ABL closure .
- Watch credit and working capital metrics (liquidity, DSOs) as filings resume; lenders’ “Specified Defaults” underscore the importance of sustained operational improvements .